Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective
Open Access
- 1 August 2012
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 23 (suppl_6), vi19-vi22
- https://doi.org/10.1093/annonc/mds190
Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous disease diagnosed by immunohistochemistry and is characterised by tumours that do not express estrogen receptor (ER) or progesterone receptor (PR) at all, and do not overexpress human epidermal growth factor receptor 2 (HER2). Prototypical TNBC is aggressive in nature and associated with a poor prognosis, making the accurate diagnosis of the disease vitally important for ensuring optimal therapy for patients. Morphological and biological analyses can identify subtypes of TNBC, which can have different prognoses, and (in the case of the latter) may eventually be used to predict response to treatment. This mini-review focuses on clinically relevant issues in the diagnosis of TNBC, including the importance of adherence to international guidelines for the detection of ER/PR/HER2 status, and the relationship between TNBC and the overlapping (yet distinct) intrinsic subtype of ‘basal-like’ breast cancer. In addition, we review the potential use of emerging biomarkers as surrogates for molecular subtypes and as a means of identifying potential responders to new therapies.Keywords
This publication has 33 references indexed in Scilit:
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals Of Oncology, 2011
- Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistryBreast Cancer Research, 2010
- Triple-negative breast cancerBreast Cancer Research, 2010
- Management of triple negative breast cancerThe Breast, 2010
- Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerAnnals Of Oncology, 2009
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals Of Oncology, 2009
- Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?Annals Of Oncology, 2009
- Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative PhenotypeClinical Cancer Research, 2008
- Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98Journal of Clinical Oncology, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007